![Stefan van den Eijnde](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stefan van den Eijnde
Direktor/Vorstandsmitglied bei Dutch Vaccines Group
Aktive Positionen von Stefan van den Eijnde
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Dutch Vaccines Group | Direktor/Vorstandsmitglied | 01.09.2009 | - |
LifetecZONe | Direktor/Vorstandsmitglied | 17.05.2010 | - |
Karriereverlauf von Stefan van den Eijnde
Ehemalige bekannte Positionen von Stefan van den Eijnde
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MUbio Holding BV
![]() MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Corporate Officer/Principal | 01.01.2003 | 05.06.2013 |
Maastricht University | Technik-/Wissenschafts-/F&E-Leiter | - | - |
NovoVacs BV | Gründer | - | - |
Ausbildung von Stefan van den Eijnde
University of Leiden | Graduate Degree |
Statistik
International
Niederlande | 7 |
Operativ
Director/Board Member | 2 |
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Sektoral
Consumer Services | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
MUbio Holding BV
![]() MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Health Technology |
NovoVacs BV | |
Dutch Vaccines Group | |
LifetecZONe |
- Börse
- Insiders
- Stefan van den Eijnde
- Erfahrung